Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

(2021) Makoto Araie et al.   ADVANCES IN THERAPY

Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients

(2020) Yuko Maruyama et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study

(2020) Shun Tsukahara et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells

(2020) Wenshi Chen et al.   Frontiers in Pharmacology

Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study

(2020) Akiko Futakuchi et al.   Scientific Reports

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients with Open-angle Glaucoma or Ocular Hypertension

(2020) Inder Paul Singh et al.   JOURNAL OF GLAUCOMA

Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution

(2019) Malik Y. Kahook et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study

(2019) Albert S. Khouri et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial

(2019) Sanjay Asrani et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)

(2018) Janet B. Serle et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil

(2018) Kenji Inoue et al.   JAPANESE JOURNAL OF OPHTHALMOLOGY

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

(2018) Cheng-Wen Lin et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension

(2018) Angelo P. Tanna et al.   OPHTHALMOLOGY

Ocular Surface Disease and Glaucoma Medications

(2018) Xuemin Zhang et al.   Eye & Contact Lens-Science and Clinical Practice

One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy

(2017) Hiroshi Inazaki et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Association between glaucoma eye drops and hyperemia

(2016) Masahide Yanagi et al.   JAPANESE JOURNAL OF OPHTHALMOLOGY

Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy

(2016) Hiroshi Inazaki et al.   JOURNAL OF GLAUCOMA

One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension

(2015) Hidenobu Tanihara et al.   ACTA OPHTHALMOLOGICA

Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension

(2015) Richard A Lewis et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Double-masked, Randomized, Dose–Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure

(2015) Jason Bacharach et al.   OPHTHALMOLOGY

Additive Intraocular Pressure–Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost

(2015) Hidenobu Tanihara et al.   JAMA Ophthalmology

Ripasudil: First Global Approval

(2014) Karly P. Garnock-Jones   DRUGS

The Pathophysiology and Treatment of Glaucoma

(2014) Robert N. Weinreb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040

(2014) Yih-Chung Tham et al.   OPHTHALMOLOGY

Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension

(2013) Hidenobu Tanihara et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome

(2013) Snježana Kaštelan et al.   Biomed Research International

Risk Factors to Develop Ocular Surface Disease in Treated Glaucoma or Ocular Hypertension Patients

(2012) Gemma Caterina Maria Rossi et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Ocular Surface Disease Exacerbated Glaucoma

(2012) Ruchika Batra et al.   JOURNAL OF GLAUCOMA

Emerging drugs for ocular hypertension

(2011) Anne J Lee et al.   EXPERT OPINION ON EMERGING DRUGS

Meta-analysis of the Efficacy and Safety of α2-Adrenergic Agonists, β-Adrenergic Antagonists, and Topical Carbonic Anhydrase Inhibitors With Prostaglandin Analogs

(2010) Angelo P. Tanna   ARCHIVES OF OPHTHALMOLOGY

Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells

(2009) Padmanabhan P. Pattabiraman et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Prevalence of Ocular Surface Disease in Glaucoma Patients

(2009) Eamon W. Leung et al.   JOURNAL OF GLAUCOMA